Tumor Conditioning Regimens: An Evolution in Cancer Treatment that Relies on Short-Term Sacrifice for Long-Term Gain
Journal Title: Gynecology and Obstetrics Research – Open Journal - Year 2017, Vol 4, Issue 2
Abstract
In this commentary, the authors discuss a new concept for tumor treatment, which is based on observations from published studies and clinical practice protocols. This new treatment regimen, which we coin “Tumor Conditioning Regimens,” abbreviated as TCRs is based on the idea that by conditioning tumors with oxygenation, increasing mutation loads or normalizing vessels, we create a permissive environment for tumor growth in the short-term, which will eventually in the long run benefit tumor regression. In our view, such a strategy of making things worse before they get better for tumor treatment has not been articulated in the literature although anecdotal examples exist, which we have highlighted in the commentary. This commentary serves as a discussion starter for the scientific and clinical community as to the pros and cons of such an approach.
Authors and Affiliations
Erin Bishop, Ramani Ramchandran
Keywords
Related Articles
- EP ID EP553846
- DOI 10.17140/GOROJ-4-143
- Views 169
- Downloads 0
Outcome of Stepwise Uterine Sparing Approach as a Conservative Surgical Management of Placenta Accreta
Introduction: The incidence of placenta accreta is rising as a consequence of increased rate of cesarean sections and placenta previa which is the strongest risk factor. Intractable postpartum hemorrhage associated with...
Abdominal and Pelvic Adhesions Research in Sub-Saharan Africa: Air Must Become Wind
Abdominal and Pelvic Adhesions (APA) are pathological fibrotic bands developed between any surfaces in the abdominal and pelvic cavities.1 They can be congenital or derive from surgery, infections, inflammation, malignan...
Interactions of Immunomodulatory HLA-G with Immune Cells during Pregnancy and Endometriosis
The Major Histocompatibility Complex (MHC), the genetic region that encodes the proteins responsible for tissue graft rejection,1 encodes MHC Class I (MHC-I) and MHC Class II (MHC-II) glycoproteins. There are two subclas...
Analyzing Pregnancy Costs with Finite Mixture Models: An Opportunity to More Adequately Accommodate the Presenceof Patient Data Heterogeneity
The choice of a model in the analysis of patient health care costs and utilization is critical for a clear understanding of the behavior and estimation of quantities like incremental costs or cost-effectiveness. In study...
Molecularly-Targeted Therapies in Gynecologic Cancer
The development of chemotherapy agents that precisely target specific molecular structures in cancer cells have become a priority in oncology research. In principle, this method halts cancer cell proliferation while allo...